• ABSTRACT
    • Over the last 2 decades the evolution of alpha-blockers for lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) has been to preserve effectiveness, improve tolerability, and eliminate dose titration. Today, alpha-blockers represent the first-line treatment of most men with BPH whereby the primary objective is relief from bothersome LUTS.